Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Clobetasol propionate
Drug ID BADD_D00490
Description Clobetasol propionate is a prednisolone derivative with higher specificity for glucocorticoid receptors than mineralocorticoid receptors.[L11815] It has demonstrated superior activity compared to [fluocinonide][A190963] and was first described in the literature in 1974.[A190936] Clobetasol Propionate was granted FDA approval on 27 December 1985.[L11809]
Indications and Usage Clobetasol propionate is indicated to treat moderate to severe plaque psoriasis[L11818,L118121,L11824] as well as inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.[L11815,L11827]
Marketing Status approved
ATC Code D07AD01
DrugBank ID DB01013
KEGG ID D01272
MeSH ID D002990
PubChem ID 32798
TTD Drug ID D0H0YD
NDC Product Code 79572-008; 42291-077; 50383-267; 51672-4193; 60429-902; 68071-2725; 0472-0403; 70771-1442; 52128-158; 16714-030; 0168-0163; 45802-437; 49502-537; 50383-269; 51672-1259; 62332-486; 63629-2393; 68382-998; 68462-529; 46439-8747; 33342-321; 43386-096; 50742-304; 51672-1258; 0299-3847; 62559-980; 63629-2395; 68462-532; 70700-106; 70710-1401; 71589-002; 0299-3849; 62332-707; 63646-500; 68180-956; 70710-1456; 71589-018; 22552-0006; 13668-569; 43538-952; 43538-953; 45802-925; 50090-5778; 50090-6402; 50383-978; 50383-979; 63629-2329; 63629-2392; 0378-8055; 68071-2764; 68788-8238; 70700-109; 71205-151; 72578-085; 51552-0605; 42571-362; 43538-950; 0168-0269; 50383-268; 51672-1293; 63629-2331; 63629-8637; 69238-1532; 71428-005; 0713-0656; 46439-8708; 49452-2141; 62991-1492; 42291-076; 63629-2332; 0591-4039; 43386-028; 0168-0162; 0168-0301; 50090-5079; 62332-465; 63629-2394; 63629-9461; 0378-8147; 68462-608; 70771-1209; 71085-007; 72189-262; 51927-2627; 40032-028; 0168-0293; 45802-637; 50090-5488; 51672-1350; 62332-548; 63629-2330; 63629-8639; 64980-441; 66993-939; 68180-536; 68462-530; 0472-0404; 70752-153; 70771-1080; 40032-096; 51672-1294; 51672-1371; 0299-3848; 62332-425; 62332-547; 63629-8638; 63629-9460; 68180-551; 68462-480; 68462-625; 69238-1732; 70771-1498; 64958-0101; 76003-0325; 16714-782; 45802-961; 50090-5264; 50383-266; 51672-1297; 51672-1347; 53002-9970
UNII 779619577M
Synonyms Clobetasol | Clofenazon | Clobetasol Propionate | Clobetasol 17-Propionate | Clobetasol 17 Propionate | Clobex | Cormax | OLUX | Dermovate | Embeline | Embeline E | Temovate
Chemical Information
Molecular Formula C25H32ClFO5
CAS Registry Number 25122-46-7
SMILES CCC(=O)OC1(C(CC2C1(CC(C3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)C(=O)CCl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Skin hypopigmentation23.05.02.003--
Skin irritation23.03.04.0090.006349%-
Skin striae23.01.05.0020.015498%-
Skin ulcer23.07.03.003; 24.04.03.0070.012697%
Small intestinal obstruction07.13.06.001--
Syncope02.11.04.015; 17.02.04.008; 24.06.02.0120.001867%
Telangiectasia23.06.03.001; 24.03.03.003--
Tenderness08.01.08.005---
Tinnitus04.04.01.002; 17.04.07.004--
Vascular purpura01.01.04.007; 23.06.01.008; 24.07.06.011---
Withdrawal syndrome08.06.02.012; 19.07.06.0230.001867%-
Skin maceration23.03.03.016---
Dermatosis23.03.03.0170.004108%-
Application site dryness08.02.01.011; 12.07.01.011; 23.03.03.024---
Emotional distress19.04.02.008---
Eye pruritus06.04.05.006---
Musculoskeletal discomfort15.03.04.0010.004108%-
Skin burning sensation17.02.06.009; 23.03.03.0210.025395%-
Dyslipidaemia14.08.04.0150.001867%-
Asteatosis23.02.07.006---
Application site discolouration08.02.01.030; 12.07.01.030; 23.03.03.023---
Connective tissue disorder10.04.04.026; 15.06.01.006---
Pituitary tumour benign05.03.05.003; 16.37.02.0010.001867%-
Immunosuppression10.03.02.001---
Lipohypertrophy14.08.04.009; 23.07.01.0050.001867%
Unevaluable event08.01.03.0510.004108%-
Erosive oesophagitis07.04.05.0040.001867%-
Application site burn08.02.01.038; 12.07.01.038; 23.03.11.013---
Central obesity14.03.02.0110.002801%-
Type 1 diabetes mellitus05.06.01.010; 10.04.08.007; 14.06.01.0100.002801%-
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages